Comparative Effectiveness of Recombinant FluBlok Quadrivalent Influenza Vaccine
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 2nd, 2024
|
The conventional influenza vaccine is typically manufactured using chicken eggs, leading to potential mutations in the hemagglutinin antigen and mismatches between the vaccine and circulating viruses. Sanofi's FluBlok Quadrivalent Influenza vaccine employs a recombinant process that eliminates the need for chicken eggs, thereby reducing the likelihood of mutation-related mismatches. The findings of a study evaluating the vaccine effectiveness of the recombinant FluBlok Quadrivalent Influenza vaccine (RIV4) have recently been published in the New England Journal of Medicine.
The extensive study spanned three distinct flu seasons between 2018 and 2021, encompassing a total of 1,630,328 participants aged 18 to 64. Among them, 74% had received the influenza vaccine during the previous flu season. Randomized assignments were made for participants to receive either the standard influenza vaccine or the recombinant FluBlok Quadrivalent Influenza vaccine. Throughout the study duration, only 2 cases of PCR-confirmed influenza infection were reported per 1,000 participants who had received the FluBlok recombinant influenza vaccine, a significantly lower infection rate compared to the standard control vaccine. The researchers determined that the FluBlok vaccine exhibited a 15.3% greater effectiveness than the conventional vaccine, with this protective effect being particularly pronounced against Influenza type A. Notably, there was marginal difference in effectiveness against type B influenza between the two vaccines. Additionally, no significant variance in hospitalization rates was observed between the recipients of the two vaccines.
The extensive study spanned three distinct flu seasons between 2018 and 2021, encompassing a total of 1,630,328 participants aged 18 to 64. Among them, 74% had received the influenza vaccine during the previous flu season. Randomized assignments were made for participants to receive either the standard influenza vaccine or the recombinant FluBlok Quadrivalent Influenza vaccine. Throughout the study duration, only 2 cases of PCR-confirmed influenza infection were reported per 1,000 participants who had received the FluBlok recombinant influenza vaccine, a significantly lower infection rate compared to the standard control vaccine. The researchers determined that the FluBlok vaccine exhibited a 15.3% greater effectiveness than the conventional vaccine, with this protective effect being particularly pronounced against Influenza type A. Notably, there was marginal difference in effectiveness against type B influenza between the two vaccines. Additionally, no significant variance in hospitalization rates was observed between the recipients of the two vaccines.